Domain Therapeutics SA

MONTREAL, Oct. 21, 2024 /PRNewswire/ - Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced initiation of dosing in its Phase 1 clinical study of FTX-101 in healthy volunteers. FTX-101 is a first-in-class therapeutic peptide that modulates the Plexin A1 / Neuropilin 1 transmembrane receptor complex in the brain to promote remyelination. Following completion of the Phase 1 clincal study, Find plans to investigate the use of FTX-101 in individuals with Chronic Optic Neuropathy – a long-term condition due to demyelination in the visual tracts of the brain and optic nerve, with serious effects on visual acuity and perception. The Phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics of FTX-101 when administered in healthy volunteers. The study is being initiated after the US Food and Drug Administration authorized initiation of the study earlier this year. The clinical study consists of two parts. Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study comprised of 40 subjects receiving FTX-101 or placebo while Part 2 is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study that will enroll 24 subjects receiving FTX-101 or placebo. "The initiation of this study is a significant milestone for both our company and individuals who suffer with Chronic Optic Neuropathy," said Philippe Douville, CEO of Find. "In this study, we will build on the large body of preclinical evidence demonstrating FTX-101's effects in models of autoimmune disease. A therapy of this type would represent a major step forward in finding the first treatment to improve the lives of people afflicted with Chronic Optic Neuropathy. We look forward to sharing data from this study in the first half of 2025." About FTX-101 Find's lead compound, FTX-101, is a first-in-class remyelinating agent that aims to restore vision to people suffering from Chronic Optic Neuropathy. FTX-101 is a rationally designed therapeutic peptide that targets Plexin A1 and Neuropilin 1, a receptor complex present in the brain that has been shown to be involved in the migration and differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes. Compelling preclinical data for FTX-101 in demyelinating models show strong myelin repair activity. About Find Find Therapeutics is clinical-stage biopharmaceutical company dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 and is supported with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec and an exclusive license from SATT-Conectus and the University of Strasbourg on a technology and related know-how. Visit for more details about Find Therapeutics. SOURCE Find Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

$8.1 million convertible note financing by Investissement Québec and current investors CTI Life Sciences Fund and adMare BioInnovations MONTREAL, Sept. 16, 2024 /PRNewswire/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced the closing of a $8.1 million (CAD$11 million) convertible note financing led by Investissement Québec with participation from current investors CTI Life Sciences Fund and adMare BioInnovations. The proceeds of the convertible note will be used to advance FTX-101 into Phase 1 clinical studies. "We are excited to welcome Investissement Québec as a new investor in Find," said Philippe Douville, CEO of Find. "With the recent clearance of the IND by the FDA and this new investment by Investissement Québec and our current investors, we are able to accelerate FTX-101 into the clinic to bring a much-needed myelin repair therapy to patients." The Phase 1 clinical trial is anticipated to commence in Q4 2024 and is designed to evaluate safety, tolerability, and pharmacokinetics of FTX-101 across different dose levels in healthy volunteers. "Investissement Québec is proud to assist Find Therapeutics in its innovation and development efforts and to help fill a gap in the capital chain for young biotech businesses," said Bicha Ngo, President and CEO of Investissement Québec. "Through our support for the company, we are contributing to the launch of its clinical studies and enabling it to deliver on the next phases of growth, with the ultimate aim of promoting better visual health." About FTX-101 Find's lead compound, FTX-101, is a first-in-class remyelinating agent that aims to restore vision in people suffering from Chronic Optic Neuropathy (CON). FTX-101 is a rationally designed therapeutic peptide that targets Plexin A1 and Neuropilin 1, a receptor complex present in the brain that has been shown to be involved in the migration and differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes. Compelling preclinical data for FTX-101 in demyelinating models show strong myelin repair activity. About Investissement Québec Investissement Québec's mission is to play an active role in Quebec's economic development by stimulating business innovation, entrepreneurship, and business acquisitions, as well as growth in investment and exports. Operating in all the province's administrative regions, the Corporation supports the creation and growth of businesses of all sizes with investments and customized financial solutions. It also assists businesses by providing consulting services and other support measures, including technological assistance available from Investissement Québec Innovation. In addition, through Investissement Québec International, the Corporation prospects for talent and foreign investment, and assists Quebec businesses with export activities. About Find Find Therapeutics is dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations and Domain Therapeutics and an exclusive license from Strasbourg University on a technology and related know-how initially developed by Dr. Dominique Bagnard. Visit for more details about Find Therapeutics. SOURCE Find Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1 study to assess safety of FTX-101, a therapeutic agent under development for regeneration of damaged myelin in Chronic Optic Neuropathy Company expects study to commence in Q4 2024 MONTREAL, Aug. 27, 2024 /PRNewswire/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for FTX-101, enabling the company to initiate its planned Phase 1 clinical study of FTX-101 in healthy volunteers. The company anticipates the commencement of the study in Q4 2024. "The FDA's clearance of our IND marks an important achievement for Find, allowing us to proceed with our Phase 1 study of FTX-101, a potentially novel remyelination therapy under development for the treatment of Chronic Optic Neuropathy, or CON," said Philippe Douville, CEO of Find. "We look forward to evaluating FTX-101 in Phase 1 clinical studies, bringing us a step closer to finding a solution for people suffering from CON for whom currently no approved therapy exists." The Phase 1 clinical trial is expected to be a single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate safety, tolerability, and pharmacokinetics of FTX-101 across different dose levels. The study is expected to enroll up to 80 participants. About FTX-101 Find's lead compound, FTX-101, is a first-in-class remyelinating agent that aims to restore vision in people suffering from Chronic Optic Neuropathy (CON). FTX-101 is a rationally designed therapeutic peptide that targets Plexin A1 and Neuropilin 1, a receptor complex present in the brain that has been shown to be involved in the migration and differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes. Compelling preclinical data for FTX-101 in demyelinating models show strong myelin repair activity. About Chronic Optic Neuropathy Chronic Optic Neuropathy is a serious and debilitating demyelinating disease of the optic nerve and visual tracts of the brain. Despite the availability of immunomodulatory drugs on the market that control inflammation and new relapses, there is a major unmet medical need to find safe and effective treatments that can repair damaged myelin in the optic nerve and visual tracts of the brain to preserve axonal function and restore vision in CON. CON affects approximately 90,000 patients in the U.S. alone. About Find Find Therapeutics is dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations and Domain Therapeutics and an exclusive license from Strasbourg University on a technology and related know-how initially developed by Dr. Dominique Bagnard. Visit for more details about Find Therapeutics. SOURCE Find Therapeutics Inc.